BiBliogrAphy 1. Ziol, m., et al., Non-invasive assessment of liver fibrosis by stiffness measurement: a prospective multicentrestudy in patients with chronic hepatitis C. hepatology, 2005. 41(1): p. 48-54. 2. marcellin, p., et al.,Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitisB. liver international, 2009. 29(2): p. 242-247. 3. chan, h.l., et al., Alanine aminotransferase-based algorithms of liver stiffness measurement by transientlastographe y (Fibroscan) for liver fibrosis in chronic hepatitis B. Journal of viral hepatitis, 2009.16(1): p. 36-44. 4. Vergara, S., et al., The use of transient elastometry for assessing liver fibrosis in patients with HIV andhepatitis C virus coinfection. clinical infectious diseases, 2007. 45(8): p. 969-74. 5. nguyen-Khac, e., et al., Assessment of asymptomatic liver fibrosis in alcoholic patients using fi- broscan: prospective coparison withm 7 non-invasive laboratory tests. alimentary pharmacology & Therapeutics, 2008. 28(10): p. 1188-98. 6. melin, p., et al., Dépistage non invasif de la fibrose : Intérêt du FibroScan en consultation d’alcoologie® [Noninvasive screening of fibrosis: interest of FibroScan in alcohol addiction consultation]. alcoolo-® gie et addictologie, 2005. 27(3): p. 191-196. 7. musso, g., et al., Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and di- agnostic accuracy of non-invasive tests for liver disease severity. annals of medicine, 2010. In press. 8. de ledinghen, V., et al., Feasibility of liver transient elastography with FibroScan(R) using a new probe for obese patients. liver international, 2010. 30(7): p. 1043-1048. 9. corpechot, c., et al.,Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. hepatology, 2006. 43(5): p. 1118-1124. 10. Friedrich-rust, m., et al., Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. gastroenterology, 2008. 134(4): p. 960-74. 11.arima, y., et al., Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitisC. hepatology research, 2010. 40(4): p. 383-92. 12. malik, r., et al., Comparison of transient elastography, serum markers and clinical signs for the di- agnosis of compensated cirrhosis. Journal of gastroenterology & hepatology, 2010. 25(9): p. 1562-8. 13. Vizzutti, F., et al., Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhos is.hepatology, 2007. 45(5): p. 1290-7. 14. masuzaki, r., et al., Prospective risk assessment for hepatocellular carcinoma development in pa- tientswith chronic hepatitis C by transient elastography. hepatology, 2009. 49(10): p. 1954-61. 15. rigamonti, c., m.F. donato, and m. colombo, Transient elastography in the early prediction of pro- gressiverecurrent hepatitis C following liver transplantation. hepatology, 2010. 52(2): p. 800-1. 16. carrión, J.a., et al.,Liver stiffness identifies two different patterns of fibrosis progression in patients with HCV recurrence after liver transplantation. hepatology, 2010. 51(1): p. 23-34. 17.laharie, d., et al., Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate forchronic inflammatory diseases: A case-control study. Journal of hepa- tology, 2010.53(6): p. 1035-40. 18. roulot, d., et al., Transient elastography as a screening tool for liver fibrosis and cirrhosis in a commnity-based population over 45 yearsu . gut, 2010. In Press. 19. Foucher, J., et al., FroScan used in street-based outreach for drug users is useful for hepatitis Cib ® virus sceening and management: a prospective studyr . Journal of Viral hepatitis, 2009. 16(2): p. 121-31. 20. menten, r., et al., Transient elastography in patients with cystic fibrosis. pediatric radiology, 2010. 40(7): p. 1231-5. 21. nobili, V., et al., Accuracy and reproducibility of transient elastographyfor the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. hepatology, 2008.48(2): p. 442-8. 22. Bonnard, p., et al., Comparison of elastography, serum marker scores, and histology for the assess- ment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. The american Journal of Tropical medicine and hygiene, 2010. 82(3): p. 454-8. 23. Sasso, m., et al., Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis -Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in medicine and Biology, 2010. 36(11): p. 1825-1835. 24. Beaugrand, m., et al. Novel ultrasonic Fibroscan-based steatosis index for hepatic steatosis quanti-® fication in 618 HCV patients in 60 Annual Meeting of the American Association for the Study of Liverth Disease. 2009. Boston, ca, USa. 25. Beaugrand, m., et al. Controlled Attenuation Parameter: a novel Fibroscan-based tool to detect and® quantify steatosis. preliminary study in patient with alcoholic and non alcoholic fatty liver disease. in 45thAnnual Meeting of the European Association for the Study of Liver. 2010. Vienna, austria. 26. cardoso, a.F., et al. Controlled Attenuation Parameter: a novel FibroScan®-based tool to detect and quantify steatosis in chronic hepatitisB. in 61Annual Meeting of the Amst erican Association for the Study of Liver Diseas . 2010. Boston, ma, USa.e 27. de ledinghen, V., et al. Non invasive diagnosis of steatosis using CAP™ by FibroScan®. in 21 Confer-st ence Meeting of the Asian Pacific Association for the Study of Liver. 2011. Bangkok, Thailand. 28. Vergniol, J., et al., non-invasive Tests for Fibrosis and liver Stiffness predict 5-year outcomes of patients with chronic hepatitis c. gastroenterology, 2011. In Press.